Prevention
Medical Masks Versus N95 Respirators for Preventing COVID-19 Among Health Care Workers
Ann Intern Med. 2022 Dec;175(12):1629-1638
Infections, Hospitalizations, and Deaths Among US Nursing Home Residents With vs Without a SARS-CoV-2 Vaccine Booster
JAMA Netw Open. 2022;5(12):e2245417.
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
N Engl J Med. 2022 Jul 7;387(1):21-34
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
BMJ. 2022 May 24;377:e071113
Detection of SARS-CoV-2 B.1.351 (Beta) Variant through Wastewater Surveillance before Case Detection in a Community, Oregon, USA
Emerg Infect Dis. 2022 Jun;28(6):1101-1109
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Euro Surveill. 2022 May;27(18):2200178.
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
N Engl J Med. 2022 May 5;386(18):1712-1720
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Engl J Med. 2022 Apr 28;386(17):1603-1614.
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
Euro Surveill. 2022 Apr;27(16):2200250
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
N Engl J Med. 2022 Apr 20;NEJMoa2116620
Immediate side effects of Comirnaty COVID-19 vaccine: A nationwide survey of vaccinated people in Israel, December 2020 to March 2021
Euro Surveill. 2022 Mar;27(13):2100540
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
NEJM 23 Mar 2022 Online ahead of print.
Fourth COVID-19 Vaccine Dose Increases Low Antibodies
JAMA. 2022 Feb 8;327(6):517.
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
N Engl J Med. 2022 Feb 16.
Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
N Engl J Med. 2022 Feb 16.
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Cell. 2022 Feb 3;185(3):457-466.e4.
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5.
Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older
JAMA. 2022 Jan 4;327(1):80-82.
Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021
Euro Surveill. 2022 Jan;27(1):2101114.
Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22
Euro Surveill. 2022 Jan;27(1):2101125.
Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021
Euro Surveill. 2022 Jan;27(2):2101197.
Homologous and Heterologous Covid-19 Booster Vaccinations
N Engl J Med. 2022 Jan 26;NEJMoa2116414.
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Lancet. 2021 Dec 18;398(10318):2277-2287.
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Nat Med. 2021 Dec;27(12):2144-2153
Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021
Euro Surveill. 2021 Dec;26(48):2101030
Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years
JAMA. 2021 Dec 7;326(21):2203-2204
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
N Engl J Med. 2021 Dec 23;385(26):2413-2420
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study
Nat Cancer. 2021 Dec;2:1321-1337
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
BMJ. 2021 Dec 16;375
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
JAMA. 2021 Nov 23;326(20):2043-2054
Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study
Clin Infect Dis. 2021 Nov 17
Association of Prior SARS-CoV-2 Infection With Risk
of Breakthrough Infection Following mRNA Vaccination in Qatar
JAMA. 2021 Nov 16;326(19):1930-1939
The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units
Clin Infect Dis. 2021 Oct 30
COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women
Sci Transl Med. 2021 Oct 27;13(617)
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
Euro Surveill. 2021 Oct 14;26(41)
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
Lancet Rheumatol. 2021 Oct;3(10):e724-e736
Rapid, dose-dependent and efficient inactivation of surface dried SARS-CoV-2 by 254 nm UV-C irradiation
Euro Surveill. 2021 Oct 21;26(42)
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
Lancet Infect Dis. 2021 Aug 16;S1473-3099(21)00451-5
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
N Engl J Med. 2021 Oct 7;385(15):1355-1371.
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
N Engl J Med. 2021 Oct 7;385(15):1393-1400.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
https://www.nejm.org/doi/full/10.1056/NEJMoa2109682
NEJM, 4 August 2021 (pre-print)
Myocarditis and Pericarditis After Vaccination for COVID-19
https://jamanetwork.com/journals/jama/fullarticle/2782900
JAMA, 4 August 2021 (pre-print)
Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
JAMA. 2021 Aug 24;326(8):728-735
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
Nat Med. 2021 Aug;27(8):1367-1369.
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
N Engl J Med. 2021 Aug 12;385(7):585-594
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Lancet. 2021 Jul 10;398(10295):121-130
Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence
European Centre for Disease Prevention and Control, 22 Jul 2021
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Lancet Oncol. 2021 Jun;22(6):765-778
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
N Engl J Med 2021; 384:1885-1898
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
N Engl J Med 2021; 384:1899-1909
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
N Engl J Med. 2021 Apr 21.
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
N Engl J Med. 2021 Feb 24.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Eng J Med. 2020 Dec 10.
First COVID-19 vaccine authorised for use in the European Union. Stockholm:
ECDC; 2020 Dec 21
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2020 Dec 30.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report.
N Engl J Med. 2020 Jul 14
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2020 Jul 20.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet. 2020 May 22.
The race for coronavirus vaccines: a graphical guide.
Nature. 2020;580(7805):576-577.
